Capricor (CAPR) Rises 2.5% Pre-Market Following August FDA Developments
CAPR Capricor Therapeutics Inc
$9.91 +3.34%
View chart & analysis → - 1Capricor Therapeutics (CAPR) rose 2.5% in pre-market trading to $10.16
- 2In mid-August, the FDA indicated its intent to review the amended BLA for deramiocel for the preservation of upper limb function in Duchenne muscular dystrophy
- 3No direct catalyst filing confirmed; shares await review following August FDA updates and Cantor Fitzgerald upgrade
This 3-line summary is compiled from the report below.
InvestorsHub +1 View original ↗
오늘의 AI 픽 5종목, 무료로 전부 공개합니다숨기는 것 없이, 지난 픽의 성적표(S&P500 대비)까지 그대로 보여드립니다